Multiple ascending doses
burns
The multiple ascending dose (MAD) study (Part E) was conducted in four cohorts in which participants received multiple dose administration of dersimelagon as a tablet or suspension formulation for 14 days in one treatment period. Each cohort was composed of 12 participants who were randomized to dersimelagon (n = 9) or placebo (n = 3). The dose levels of dersimelagon used were 30 mg (Cohort 1, suspension), 150 mg (Cohort 2, tablet), 300 mg (Cohort 3, tablet), and 450 mg (Cohort 4, tablet). A Fitzpatrick scale test was performed at screening to categorize patient skin types into type I (always burns, never tans), type II (usually burns, tans with difficulty), type III (sometimes mild burn, gradually tans), type IV (rarely burns, tans with ease), type V (very rarely burns, tans very easily), or type VI (never burns, always tans) [